Lyra Therapeutics to Report Second Quarter 2020 Financial Results and Provide Corporate Update
July 24, 2020 08:30 ET
|
Lyra Therapeutics
WATERTOWN, Mass., July 24, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
Lyra Therapeutics Announces Robert Richard, Ph.D., as Senior Vice President of Research and Development
July 07, 2020 08:30 ET
|
Lyra Therapeutics
WATERTOWN, Mass., July 07, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
Derm-Biome Pharmaceuticals, Inc raises pre-seed funding, spins out new company focused on chronic inflammatory diseases
July 02, 2020 11:00 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, July 02, 2020 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on skin diseases and healthy ageing,...
Corbus Pharmaceuticals Presents Data Demonstrating ACR CRISS Score Reflects Patient-Reported Outcomes at 6th Systemic Sclerosis World E-Congress
June 29, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Phase 2 systemic sclerosis (SSc) analyses show ACR CRISS score correlates with improvements from baseline in how patients feel and function through two years in the lenabasum Phase 2 open-label...
Lyra Therapeutics Set to Join the Russell 2000® Index and Russell 3000® Index
June 25, 2020 08:00 ET
|
Lyra Therapeutics
WATERTOWN, Mass., June 25, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
Lyra Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 28, 2020 16:05 ET
|
Lyra Therapeutics
WATERTOWN, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
Chronic Obstructive Pulmonary Disease Market Size Worth Around USD 24.3 Billion by 2026: Acumen Research and Consulting
February 19, 2019 07:00 ET
|
Acumen Research and Consulting
According to a new research report titled ‘Chronic Obstructive Pulmonary Disease Treatment Market (By Drug Class: Bronchodilators, Combination, Phosphodiesterase Type 4 Inhibitors, Mucokinetics,...
BioDelivery Sciences Announces Further Significant Expanded Preferred Coverage For BELBUCA®
November 01, 2018 16:10 ET
|
BioDelivery Sciences International, Inc.
More than 100 million Covered Lives Now Have Preferred Access to BELBUCA RALEIGH, N.C., Nov. 01, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly...
BioDelivery Sciences to Report Second-Quarter 2018 Financial Results on August 9, 2018
July 24, 2018 16:30 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., July 24, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced that it will report its second quarter 2018 financial results after the close...
Corbus Pharmaceuticals Announces Resolution of Inflammation, Infection and Tissue Regeneration Conference
June 21, 2018 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
The New York Academy of Sciences symposium will highlight cutting edge research across the fields of inflammation, infection, and tissue regeneration, with focus on novel resolution mediators and...